India, April 22 -- Akeso Inc. announced that its PD-1/VEGF bispecific antibody, ivonescimab, in combination with chemotherapy, has demonstrated strongly positive results in the Phase III clinical trial (AK112-306/HARMONi-6) for first-line treatment of advanced squamous non-small cell lung cancer or sq-NSCLC.
The Independent Data Monitoring Committee or IDMC declared that the study had met its primary endpoint of progression-free survival at the first pre-specified interim analysis. The results of HARMONi-6 study are both statistically significant and clinically meaningful, the company said in a statement.
Data from the HARMONi-6 study show that, in the intention-to-treat population, ivonescimab plus chemotherapy decisively beat tislelizum...